Chantal Mathieu, M.D., P.h.D.
Katholieke Universiteit Leuven, Belgium
Chantal Mathieu is Professor of Medicine at the Katholieke Universiteit Leuven, Belgium. She serves as the Chair of Endocrinology at the University Hospital Gasthuisberg Leuven, Senior Vice President of EASD, and Chair of Postgraduate Education at EASD.
Chantal’s clinical areas of interest include the organization of diabetes care. She is involved in several clinical trials in type 1 and type 2 diabetes. Her research is focused on the prevention of T1D, effects of vitamin D on the immune system and diabetes, and functioning of the insulin-producing beta cell. Chantal has authored or co-authored more than 350 peer-reviewed publications in international journals. In 2013, she received the prestigious InBev-Baillet Latour Prize for Clinical Research for her pioneering research on the pathogenesis of T1D. Presently, she coordinates the INNODIA project on prevention and intervention in T1D in Europe.
Chantal received her M.D. and Ph.D. at the University of Leuven, where she subsequently completed training in internal medicine and endocrinology.
Maria Ines Schmidt. M.D., P.h.D.
Universidade Federal do Rio Grande do Sul, Brazil
Prof. Schmidt graduated in Medicine in 1973 and specialized in Endocrinology between 1974-1975 in Porto Alegre, RS. She continued her training in endocrinology as a postdoctoral fellow at Johns Hopkins (1976-1978) and NC Memorial (1980-1981) hospitals. She completed her training in Epidemiology at the University of North Carolina (Masters between 1979-1981; PhD between 1981-1983; postdoctoral between 1991-1992). She is a professor at the Federal University of Rio Grande do Sul, working in the Graduate Program in Epidemiology. She participated in research and graduate evaluation committees at UFRGS, FAPERGS, CNPq and CAPES. She has served as a member of epidemiology committees in national and international professional societies. She has participated in the development of diabetes-related guidelines for national and international bodies including the World Health Organization and the International Diabetes Federation. She is a full member of the Brazilian Academy of Sciences. It develops investigations on diabetes mellitus and other chronic non-communicable diseases, including metabolic syndrome and obesity, With the tools of epidemiology, it seeks to show the global importance of chronic non-communicable diseases and to understand current epidemics that share causal routes such as obesity, diabetes cardiovascular diseases. His causality models consider the analogies between the acute response of the innate immune system and the chronic and mild response to stressors in the modern environment.
Dr. Harpreet Singh Bajaj, M.D., P.h.D.
LMC Healthcare, Canada
Dr. Harpreet Singh Bajaj started his Endocrinology practice with LMC Brampton in 2009, after completing his clinical fellowship at the Cleveland Clinic (Ohio, USA). Dr. Bajaj’s medical education was at Maulana Azad Medical College (New Delhi, India), following which he attained a Masters of Public Health (Epidemiology) at State University of New York in Albany (New York, USA).
Dr. Bajaj is the Director of Late-phase research at LMC, a Research Associate at Mount Sinai Hospital, Toronto and an adjunct lecturer at McMaster University. He has co-authored publications in key medical journals in the fields of diabetes, obesity and cardiovascular risk assessment. His major interest lies in translational research focused on “real-life” practical approaches to improve standards of practice to reduce diabetes complications and cardiovascular risk factors.
He volunteers with numerous community public health organizations as well as media programs with the intent of raising public awareness on diabetes prevention and treatment, with a specific focus on the South Asian origin population in Canada. He is the founder of STOP Diabetes Foundation, a registered charitable organization, working to reduce the burden of diabetes in Peel region of Ontario.
Dr. Bajaj serves Diabetes Canada as a co-chair of the Communications and Marketing portfolio within the professional section national executive, as a national consultant editor for the Canadian Journal for Diabetes and as an expert committee member for the 2018 Clinical Practice Guidelines. He has recently been appointed as the Vice-Chair of Diabetes Canada’s Clinical Practice Guidelines (CPG) for a 3 year term; with the expectation that, at the end of the 3-year term, the Vice-Chair will take over as CPG Chair.
Laurens Van Kleef, M.D.
Erasmus MC Medical Center, Rotterdam, The Netherlands
In 2020 he started a PhD program at the hepatology department under the supervision of dr. Robert J. de Knegt and prof. Robert A. de Man at the Erasmus MC Medical Center, Rotterdam, The Netherlands. During this program, he published >30 articles on fatty liver disease in the general population. More specifically on the impact of the transition from NAFLD to MAFLD, considerations in early detection of advanced liver disease and potential targets for disease prevention/treatment and management. He became a Deplhi panel member for the renaming of NAFLD and he mastered abdominal ultrasound and transient elastography. In January 2023, he successfully defended his thesis, whereafter he began the postgraduate training in Gastroenterology and Hepatology.
Frances Game, M.D., Prof.
University Hospitals of Derby and Burton NHS Foundation Trust
Professor Fran Game has been a consultant Diabetologist at University Hospitals of Derby and Burton NHS Foundation Trust since 2011. She is also the Clinical Director of R&D and the Derby Clinical Trials Support unit.
Her main clinical and research interest is the Diabetic Foot and she has published over 80 papers and book chapters on the subject. She has an active research interest, running several multicentre/multinational trials in this field. She is especially interested in service development, particularly the need to manage diabetic foot disease in a more cost-effective way, closer to home for patients. She is an active teacher both locally, nationally and internationally, being regularly asked to lecture at major diabetes conferences. She has worked with Diabetes UK on their Putting Feet First campaign. She chairs the Classification Subgroup of the IWGDF, co-chairs the East Midlands Diabetic Foot Network and was appointed the NHS England Co-Clinical Director for Diabetes and Vascular Diseases for the East Midlands in May 2018.
Stephen Colagiuri, M.D., Prof.
Prof. Emeritus The Boden Institute, University of Sydney
Stephen Colagiuri is Professor of Metabolic Health and Director of The Boden Institute at the University of Sydney. He is also Co-Director, World Health Organization Collaborating Centre on Physical Activity, Nutrition and Obesity.
His research interests focus on the development and implementation of evidence-based guidelines, cardiometabolic and vascular risk assessment, diabetes screening and prevention, economic aspects of diabetes and obesity, and diabetes care delivery.
He has previously served as President of the Australian Diabetes Society and Chair of the International Diabetes Federation Task Force on Clinical Guidelines. He is a member of the Diabetes Expert Advisory Committee of the Commonwealth Department of Health and an advisor on diabetes to the World Health Organization.
Professor Colagiuri is currently Editor-in-Chief of the IDF journal, Diabetes Research and Clinical Practice, and has published over 200 scientific papers.
Pablo Aschner, Prof., M.D., M.Sc.
Javeriana University School of Medicine
Prof. Pablo Aschner Montoya is an Associate Professor of Endocrinology at the Javeriana University School of Medicine and Senior Research Advisor at San Ignacio University Hospital. He is also the Scientific Director of the Colombian Diabetes Association.
He graduated in Medicine and Surgery from the Javeriana University, Bogotá, in 1974 and undertook postgraduate training in Internal Medicine and Endocrinology at the Military Hospital, Bogotá, and at Cambridge University, UK, qualifying as an Endocrinologist in 1982. He has also a Master Degree in Clinical Epidemiology.
Professor Aschner has served as a member of the WHO Expert Advisory Panel on chronic degenerative diseases and the IDF taskforce on Guidelines. He is also a Faculty member of the Cambridge Diabetes Seminar and the Latin American Diabetes Epidemiology Course and founding member of the World Community for the Prevention of Diabetes. He has been president of the Colombian Endocrine Society and the Latin American Diabetes Association (ALAD).
Professor Aschner's main research interests include prevention of type 2 diabetes in the real world as well as diagnosis, control and treatment of diabetes and its complications, with emphasis on the development of evidence-based clinical guidelines. He has authored, or co-authored, over 100 abstracts, articles and book chapters in the field of diabetes research.
A K Azad Khan, M.D.
Birdem General Hospital & Ibrahim Medical College
Prof. Dr. A. K. Azad Khan is a Medicine Specialist in Dhaka. His qualification is MBBS (Dhaka), D-Phil, FCPS (Medicine), FRCP (UK). He is a Professor in the Department of Gastroenterology at Birdem General Hospital & Ibrahim Medical College. He regularly provides treatment to his patients at BIRDEM Specialised Chamber Complex.
Manoj Chaddha, MD, DM (Endocrinology), FICP
Senior Consultant Endocrinologist at P.D. Hinduja Hospital and Research Centre, Mumbai
Dr. Manoj Chadha trained at University of Ulm, Germany in use of artificial pancreas (Biostator)
Immediate past President of Indian Society of Bone Mineral Research. (ISBMR) (2017-19) & Past President Endocrine Society of India (2017-18)
Conferred the Fellowship of Indian College of Physicians (FICP- 2001) and Royal College of Physicians of Ireland (FRCPI-2004)
Publications and Chapters: 60 in National & International journals
Subhankar Chowdhury, M.D., Prof.
Professor and Head, Dept. of Endocrinology, IPGME&R and SSKM Hospital, Kolkata.
Former Editor-in-Chief, Indian Journal of Endocrinology and Metabolism
Past President, Endocrine Society of India; Past Secretary, RSSDI
Member, Subject Expert Committee, CDSCO, Govt. of India
Founder Patron, South Asian Federation of Endocrine Societies
>210 publications in various national and international journals
Bipin Kumar Sethi, MD, DM (Endocrinology- PGIMER, Chandigarh)
Consultant Endocrinologist with CARE Hospitals in Hyderabad.
Dr. Sethi completed his MBBS from Osmania Medical College in Hyderabad and MD in Medicine and DM Endocrinology from PGIMER Chandigarh.
Recipient of Economic times - Inspiring Doctors of India Award 2018 (New Delhi)
Over the years, he has authored as well as contributed to innumerable papers connected to his field of expertise, which has been published in peer-reviewed journals.
Anil Bhansali, MD, DM (Endocrinology), FRCP
Director, Gini Health, Mohali
Erstwhile Head Department of Endocrinology PGIMER, Chandigarh
>500 publications with H index 60 ; >20K citations
Dr B. C. Roy awardee
Former President of ESI and Punjab RSSDI
Author of Clinical Rounds in Endocrinology
Jennifer Green, M.D.
Dr. Jennifer Green is a professor of medicine in the division of endocrinology, metabolism, and nutrition at Duke University and a faculty member of the Duke Clinical Research Institute. Her research has focused upon strategies to treat diabetes mellitus and reduce the risk of cardiovascular, kidney and other diabetes-related complications. Her work with the DCRI has included protocol development, oversight of adjudication committees, and clinical and operational leadership for several large, international trials designed to determine the cardiovascular effects of glucose-lowering medications (TECOS, EXSCEL, and Harmony Outcomes). She currently serves as US coordinating center PI and US national representative for the EMPA-Kidney trial of empagliflozin therapy in patients with chronic kidney disease. Dr. Green has concluded three years of service as a member of the American Diabetes Association’s (ADA) Professional Practice Committee, which publishes the organization’s annual Standards of Care in Diabetes. She is now a member of the ADA-EASD writing group which recently revised a joint consensus statement on the management of hyperglycemia in type 2 diabetes.